phylloquinoneWhat was measured
Measured, with no finding
918 endpoints
Show what was measuredHide what was measured
baseline %carbOC correlation with BMD of femoral neck
increases
Baseline %carbOC of the entire study population was positively correlated with BMD of the lumbar spine and femoral neck
PMID 10951511 · one of two readings recorded this
baseline %carbOC correlation with BMD of lumbar spine
increases
Baseline %carbOC of the entire study population was positively correlated with BMD of the lumbar spine and femoral neck
PMID 10951511 · one of two readings recorded this
maximum increase in serum 25-hydroxyvitamin D [25(OH)D]
increases
One year of supplementation with vitamin D(3) showed maximum increases in 25(OH)D of 33+/-29% (95% CI, 24.8-41.8%) and 68+/-58% (95% CI, 50.1-84.6%) in women with normal and low BMD, respectively
PMID 10951511 · one of two readings recorded this
maximum increase in serum 25-hydroxyvitamin D [25(OH)D]
increases
One year of supplementation with vitamin D(3) showed maximum increases in 25(OH)D of 33+/-29% (95% CI, 24.8-41.8%) and 68+/-58% (95% CI, 50.1-84.6%) in women with normal and low BMD, respectively
PMID 10951511 · one of two readings recorded this
percentage carboxylated osteocalcin (%carbOC)
unclear
((mean+/-s.d.) 68+/-11% (95% CI, 64. 5-71.2%) vs 72+/-6% (95% CI, 70.1-72.9%)
PMID 10951511 · one of two readings recorded this
percentage carboxylated osteocalcin (%carbOC)
unclear
((mean+/-s.d.) 68+/-11% (95% CI, 64. 5-71.2%) vs 72+/-6% (95% CI, 70.1-72.9%)
PMID 10951511 · one of two readings recorded this
winter decline in maximum 25(OH)D levels
decreases
During winter, however, a 29% decline in maximum 25(OH)D levels was not prevented in women with low BMD
PMID 10951511 · one of two readings recorded this
baseline serum phylloquinone concentration
unclear
At baseline, the mean serum phylloquinone concentration was lower in the young than in the old group; there was no effect of sex
PMID 11101481 · one of two readings recorded this
baseline %ucOC
unclear, p = 0.0001
Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P: < 0.0001) but did not differ significantly by age in women
PMID 11101481 · one of two readings recorded this
baseline %ucOC
no effect
Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P: < 0.0001) but did not differ significantly by age in women
PMID 11101481 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC) in serum, before and after 1000 microg/d phylloquinone or placebo for 2 weeks
decreases
Not recorded as a finding: a node exists but the paper states a different instrument or population
Among all supplemented groups, mean %ucOC decreased from 7.6% to 3. 4% without significant differences by age or sex; 102 of 112 subjects had a >1% decrease.
PMID 11101481 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
decreases
Among all supplemented groups, mean %ucOC decreased from 7.6% to 3. 4% without significant differences by age or sex
PMID 11101481 · one of two readings recorded this
serum bone-specific alkaline phosphatase (BSAP)
no effect
Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration
PMID 11101481 · one of two readings recorded this
serum N-telopeptides of type I collagen (NTx)
no effect
Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration
PMID 11101481 · one of two readings recorded this
serum phylloquinone concentration
increases, p = 0.0001
After supplementation, serum phylloquinone concentration increased approximately 10-fold (P: < 0.0001) at week 1 (from 0.93 +/- 0.08 to 8.86 +/- 0.70 nmol/L, x+/- SEM)
PMID 11101481 · one of two readings recorded this
subjects with a >1% decrease in %ucOC
decreases, n = 112
102 of 112 subjects had a >1% decrease
PMID 11101481 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC) in serum across phylloquinone doses of 250 to 2000 microg/d versus placebo
decreases, %ucOC decreased dose-dependently; 250 microg/d differed from placebo; 1000 differed from 500 microg/d
Not recorded as a finding: a node exists but the paper states a different instrument or population
Phylloquinone supplementation decreased %ucOC dose-dependently; %ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups.
PMID 12399278 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
decreases
%ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups
PMID 12399278 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
decreases, p = 0.0001
In substudy A, %ucOC decreased with phylloquinone supplementation (P < 0.0001); a greater reduction was observed with 1000 and 2000 micro g than with 500 micro g (P < 0.05)
PMID 12399278 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
decreases, p = 0.05
In substudy A, %ucOC decreased with phylloquinone supplementation (P < 0.0001); a greater reduction was observed with 1000 and 2000 micro g than with 500 micro g (P < 0.05)
PMID 12399278 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
decreases
%ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups
PMID 12399278 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
decreases, p = 0.0001
In substudy B, %ucOC decreased in all supplemented groups by week 1 (P for the trend < 0.0001), which was sustained through week 2
PMID 12399278 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC)
no effect
%ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups
PMID 12399278 · one of two readings recorded this
Elevated serum PIVKA-II at admission
n = 18
At admission, 18 infants (41%) had elevated levels of serum PIVKA-II and eight (18%) had low K(1) concentrations, indicative of subclinical vitamin K deficiency
PMID 12598499 · one of two readings recorded this
Infants achieving incremental rise in serum K1 > 10 ng/ml after oral dose
n = 24
The severity of malabsorption was such that only 4/24 (17%) achieved an incremental rise in serum K(1) > 10 ng/ml
PMID 12598499 · one of two readings recorded this
Median serum vitamin K1 24 hours after oral dose, cholestatic infants
In the latter group, the low median value (0.95 ng/ml) and wide range (< 0.15-111 ng/ml) of serum K(1) compared unfavourably with the much higher levels (median 77, range 11-263 ng/ml) observed in healthy infants given the same oral dose
PMID 12598499 · one of two readings recorded this
Median serum vitamin K1 24 hours after oral dose, healthy newborns
n = 14
In the latter group, the low median value (0.95 ng/ml) and wide range (< 0.15-111 ng/ml) of serum K(1) compared unfavourably with the much higher levels (median 77, range 11-263 ng/ml) observed in healthy infants given the same oral dose
PMID 12598499 · one of two readings recorded this
Median serum vitamin K1 at baseline
no effect
Median serum K(1) concentrations were similar in the oral and intravenous groups at baseline (0.92 v 1.15 ng/ml), rising to 139 ng/ml six hours after intravenous K(1) but to only 1.4 ng/ml after oral administration
PMID 12598499 · one of two readings recorded this
Median serum vitamin K1 six hours after dose
increases
Median serum K(1) concentrations were similar in the oral and intravenous groups at baseline (0.92 v 1.15 ng/ml), rising to 139 ng/ml six hours after intravenous K(1) but to only 1.4 ng/ml after oral administration
PMID 12598499 · one of two readings recorded this
Median serum vitamin K1 six hours after dose
increases
Median serum K(1) concentrations were similar in the oral and intravenous groups at baseline (0.92 v 1.15 ng/ml), rising to 139 ng/ml six hours after intravenous K(1) but to only 1.4 ng/ml after oral administration
PMID 12598499 · one of two readings recorded this
Blood coagulability, factor VII and X activities, PIVKA-II concentrations
no effect
Although vitamin K1 concentrations were statistically significantly higher in the intramuscular group, blood coagulability, activities of factors VII and X and PIVKA-II concentrations did not reveal any difference between the two groups
PMID 1444522 · one of two readings recorded this
Infants with detectable PIVKA-II
increases
At 3 months vitamin K1 concentrations were back at unsupplemented values and PIVKA-II was detectable in 11.5% of infants
PMID 1444522 · one of two readings recorded this
PIVKA-II detectable
decreases
At 2 weeks of age vitamin K1 concentrations were raised compared with reported unsupplemented concentrations and no PIVKA-II was detectable
PMID 1444522 · one of two readings recorded this
Plasma vitamin K1 concentration
increases
Although vitamin K1 concentrations were statistically significantly higher in the intramuscular group, blood coagulability, activities of factors VII and X and PIVKA-II concentrations did not reveal any difference between the two groups
PMID 1444522 · one of two readings recorded this
common carotid artery intima-media thickness, distensibility coefficient, compliance coefficient, pulse pressure and Young's modulus over three years
no effect, no significant differences in the change of IMT between the three groups
Not recorded as a finding: the intervention held more than the compound
No significant differences were observed in the change of IMT between the three groups.
PMID 14961167 · one of two readings recorded this
compliance coefficient (CC) decrease
decreases, p = 0.05
Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)
PMID 14961167 · one of two readings recorded this
distensibility coefficient (DC) decrease
decreases, p = 0.05
Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)
PMID 14961167 · one of two readings recorded this
elastic properties (DC, CC, PP, E)
no effect
There were no significant differences between the MD-group and placebo
PMID 14961167 · one of two readings recorded this
intima-media thickness (IMT) change
no effect
No significant differences were observed in the change of IMT between the three groups
PMID 14961167 · one of two readings recorded this
pulse pressure (PP) increase
increases, p = 0.05
Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)
PMID 14961167 · one of two readings recorded this
Young's Modulus (E) increase
increases, p = 0.01
Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)
PMID 14961167 · one of two readings recorded this
BMC of lumbar spine, lean tissue mass and fat mass by DXA; carboxylated and undercarboxylated osteocalcin
increases, lumbar spine BMC P = 0.001, lean tissue mass P = 0.016, fat mass P = 0.014, treatment vs placebo
Not recorded as a finding: the intervention held more than the compound
Furthermore, there was a statistically significant increase in BMC of lumbar spine (P = 0.001), lean tissue mass (LTM: P = 0.016) and fat mass (FM: P = 0.014) in the treatment group when compared to the placebo group.
PMID 16782422 · one of two readings recorded this
bone mineral content (BMC) of lumbar spine
increases, p = 0.001
a statistically significant increase in BMC of lumbar spine (P = 0.001)
PMID 16782422 · one of two readings recorded this
bone mineral content (BMC) of lumbar spine
increases, p = 0.015
The significant increase in BMC of lumbar spine in the treatment group was present only in the prepubertal children (P = 0.015)
PMID 16782422 · one of two readings recorded this
bone mineral content (BMC) of lumbar spine
no effect
The significant increase in BMC of lumbar spine in the treatment group was present only in the prepubertal children (P = 0.015)
PMID 16782422 · one of two readings recorded this
carboxylated osteocalcin (cOC) concentration
increases, p = 0.001
carboxylated osteocalcin (cOC) concentration significantly increased (P < 0.001)
PMID 16782422 · one of two readings recorded this
carboxylated osteocalcin (cOC) concentration
increases, p = 0.001
in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)
PMID 16782422 · one of two readings recorded this
carboxylated osteocalcin (cOC) concentration
increases, p = 0.004
in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)
PMID 16782422 · one of two readings recorded this
fat mass (FM)
increases, p = 0.014
fat mass (FM: P = 0.014)
PMID 16782422 · one of two readings recorded this
lean tissue mass and fat mass by DXA; lumbar spine BMC; carboxylated and undercarboxylated osteocalcin
increases
Not recorded as a finding: the intervention held more than the compound
Furthermore, there was a statistically significant increase in BMC of lumbar spine (P = 0.001), lean tissue mass (LTM: P = 0.016) and fat mass (FM: P = 0.014) in the treatment group when compared to the placebo group.
PMID 16782422 · one of two readings recorded this
lean tissue mass (LTM)
increases, p = 0.016
lean tissue mass (LTM: P = 0.016)
PMID 16782422 · one of two readings recorded this
undercarboxylated osteocalcin (ucOC) concentration
decreases, p = 0.001
undercarboxylated osteocalcin (ucOC) concentration significantly decreased (P = 0.001)
PMID 16782422 · one of two readings recorded this
undercarboxylated osteocalcin (ucOC) concentration
decreases, p = 0.006
in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)
PMID 16782422 · one of two readings recorded this
undercarboxylated osteocalcin (ucOC) concentration
decreases, p = 0.042
in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)
PMID 16782422 · one of two readings recorded this
cross-linked C-telopeptide of type I collagen
decreases
cross-linked C-telopeptide of type I collagen >30%, total osteocalcin and type I N-terminal procollagen peptide >15%
PMID 17030114 · one of two readings recorded this
serum phylloquinone
increases, p = 0.05
In vitamin K-supplemented women, mean serum phylloquinone concentrations increased from 0.27 to 0.76 microg/L (P < 0.05)
PMID 17030114 · one of two readings recorded this
serum undercarboxylated osteocalcin (microg/L) and serum phylloquinone over 16 weeks in women given high-calcium skim milk with added phylloquinone 80 microg/d
decreases, undercarboxylated osteocalcin fell from 9.68 to 4.46 microg/L within the vitamin K-supplemented group
Not recorded as a finding: the result compares a group with itself, not with a control
In vitamin K-supplemented women, mean serum phylloquinone concentrations increased from 0.27 to 0.76 microg/L (P < 0.05) and undercarboxylated osteocalcin concentrations decreased from 9.68 to 4.46 microg/L (P < 0.05) over 16 wk.
PMID 17030114 · one of two readings recorded this
total osteocalcin and type I N-terminal procollagen peptide
decreases
cross-linked C-telopeptide of type I collagen >30%, total osteocalcin and type I N-terminal procollagen peptide >15%
PMID 17030114 · one of two readings recorded this
undercarboxylated osteocalcin
decreases, p = 0.05
undercarboxylated osteocalcin concentrations decreased from 9.68 to 4.46 microg/L (P < 0.05)
PMID 17030114 · one of two readings recorded this
bone mineral at mid-distal radius
no effect
Significant bone mineral loss was seen only at the mid-distal radius but with no significant difference between groups
PMID 17243866 · one of two readings recorded this
bone mineral at mid-distal radius
decreases
Significant bone mineral loss was seen only at the mid-distal radius but with no significant difference between groups
PMID 17243866 · one of two readings recorded this
bone mineral content and density at the ultradistal radius, DXA
increases, modest significant increase in BMC at the ultradistal radius, not at other hip or radius sites
Not recorded as a finding: the intervention held more than the compound
Combined vitamin K with vitamin D plus calcium was associated with a modest but significant increase in BMC at the ultradistal radius but not at other sites in the hip or radius.
PMID 17243866 · one of two readings recorded this
bone mineral content at other hip and radius sites
no effect
Combined vitamin K with vitamin D plus calcium was associated with a modest but significant increase in BMC at the ultradistal radius but not at other sites in the hip or radius
PMID 17243866 · one of two readings recorded this
bone mineral content at ultradistal radius
increases
Combined vitamin K with vitamin D plus calcium was associated with a modest but significant increase in BMC at the ultradistal radius but not at other sites in the hip or radius
PMID 17243866 · one of two readings recorded this
bone mineral density at ultradistal radius
increases
women who took combined vitamin K and vitamin D plus calcium showed a significant and sustained increase in both BMD and BMC at the site of the ultradistal radius
PMID 17243866 · one of two readings recorded this
parathyroid hormone (PTH)
decreases, p = 0.049
Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)
PMID 17243866 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%GluOC)
decreases, p = 0.001
Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)
PMID 17243866 · one of two readings recorded this
serum 25-hydroxyvitamin D
increases, p = 0.001
Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)
PMID 17243866 · one of two readings recorded this
serum vitamin K1
increases, p = 0.001
Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)
PMID 17243866 · one of two readings recorded this
serum bone-specific alkaline phosphatase and urinary bone resorption markers (NTx, pyridinoline, deoxypyridinoline)
no effect, unaffected by phylloquinone supplementation
Not recorded as a finding: no outcome node for bone-specific ALP or urinary resorption markers; the alkaline-phosphatase node is total serum ALP
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation.
PMID 17298708 · one of two readings recorded this
serum bone-specific alkaline phosphatase, assay not stated
no effect
Not recorded as a finding: listed alkaline-phosphatase node is total serum ALP by para-nitrophenyl-phosphate assay; paper measured the bone-specific isoform
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation.
PMID 17298708 · one of two readings recorded this
serum bone-specific alkaline phosphatase
no effect
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation
PMID 17298708 · one of two readings recorded this
serum gamma-carboxylated osteocalcin
increases, p = 0.001
the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001)
PMID 17298708 · one of two readings recorded this
serum phylloquinone concentration, assay not stated
increases
Not recorded as a finding: no outcome node for circulating phylloquinone
Mean serum phylloquinone concentration was significantly (P < 0.001) higher with daily supplementation with 500 microg phylloquinone/d compared with that during either of the placebo or 200 microg phylloquinone/d supplementation periods, which did not differ (P = 0.15).
PMID 17298708 · one of two readings recorded this
serum phylloquinone concentration
no effect, p = 0.15
Mean serum phylloquinone concentration was significantly (P < 0.001) higher with daily supplementation with 500 microg phylloquinone/d compared with that during either of the placebo or 200 microg phylloquinone/d supplementation periods, which did not differ (P = 0.15)
PMID 17298708 · one of two readings recorded this
serum phylloquinone concentration
increases, p = 0.001
Mean serum phylloquinone concentration was significantly (P < 0.001) higher with daily supplementation with 500 microg phylloquinone/d compared with that during either of the placebo or 200 microg phylloquinone/d supplementation periods, which did not differ (P = 0.15)
PMID 17298708 · one of two readings recorded this
serum total osteocalcin
increases, increased with 500 but not 200 microg/d vs placebo
Not recorded as a finding: no outcome node for total osteocalcin
Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo.
PMID 17298708 · one of two readings recorded this
serum total osteocalcin
no effect
Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo
PMID 17298708 · one of two readings recorded this
serum total osteocalcin
increases, p = 0.001
Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo
PMID 17298708 · one of two readings recorded this
serum under-gamma-carboxylated osteocalcin
decreases, p = 0.001
the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001)
PMID 17298708 · one of two readings recorded this
urinary deoxypyridinoline
no effect
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation
PMID 17298708 · one of two readings recorded this
urinary gamma-carboxyglutamate
no effect
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation
PMID 17298708 · one of two readings recorded this
urinary N-telopeptide cross-links of collagen
no effect
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation
PMID 17298708 · one of two readings recorded this
urinary pyridinoline
no effect
Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation
PMID 17298708 · one of two readings recorded this
maximal INR stability
increases
The relative risk (RR) of a maximal stability in the vitamin K group compared to the placebo group was 1.8 (95%, CI 1.1-2.7)
PMID 17666020 · one of two readings recorded this
percentage of time the INR was within the therapeutic range (primary outcome)
adjusted difference 3.6%; 95% CI -0.8% to 8.0%
Not recorded as a finding: the paper never states the instrument the node requires
The time in the therapeutic range was 85.5% in the placebo group and 89.5% in the vitamin K group (adjusted difference 3.6%; 95% CI -0.8% to 8.0%).
PMID 17666020 · both readings recorded this
time above the therapeutic INR range
no effect
the time above the therapeutic range was 11.4% in the placebo group and 8.5% in the vitamin K group (adjusted difference -2.9%; 95% CI -6.9% to 1.1%)
PMID 17666020 · one of two readings recorded this
time below the therapeutic INR range
no effect
The time below the therapeutic range was 3.1% in the placebo group and 2.1% in the vitamin K group (adjusted difference -0.7%; 95% CI -2.5% to 1.1%)
PMID 17666020 · one of two readings recorded this
time in the therapeutic INR range
no effect
The time in the therapeutic range was 85.5% in the placebo group and 89.5% in the vitamin K group (adjusted difference 3.6%; 95% CI -0.8% to 8.0%)
PMID 17666020 · one of two readings recorded this
3-year change in femoral neck, spine (L2-L4) and total-body BMD, and percent undercarboxylated osteocalcin, with 500 ug/day phylloquinone in a multivitamin versus multivitamin without phylloquinone
no effect, no differences in BMD change at any site measured between the two groups
Not recorded as a finding: the supporting sentence never names the compound
There were no differences in changes in BMD measurements at any of the anatomical sites measured between the two groups.
PMID 18252784 · one of two readings recorded this
change in BMD at femoral neck, spine and total body
no effect, n = 401
There were no differences in changes in BMD measurements at any of the anatomical sites measured between the two groups
PMID 18252784 · one of two readings recorded this
femoral neck, spine (L2-L4) and total-body BMD change over 3 years, phylloquinone 500 ug/d in a multivitamin versus multivitamin without phylloquinone
no effect, no differences in BMD changes at any site between the two groups
Not recorded as a finding: the supporting sentence never names the compound
There were no differences in changes in BMD measurements at any of the anatomical sites measured between the two groups.
PMID 18252784 · one of two readings recorded this
other biochemical measures (bone turnover, vitamin D status)
no effect
No other biochemical measures differed between the two groups
PMID 18252784 · one of two readings recorded this
percent undercarboxylated osteocalcin
decreases
The group that received the phylloquinone supplement had significantly higher phylloquinone and significantly lower percent undercarboxylated osteocalcin concentrations compared with the group that did not receive phylloquinone
PMID 18252784 · one of two readings recorded this
plasma phylloquinone
increases
The group that received the phylloquinone supplement had significantly higher phylloquinone and significantly lower percent undercarboxylated osteocalcin concentrations compared with the group that did not receive phylloquinone
PMID 18252784 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%Glu-OC) and serum vitamin K1 in cystic fibrosis children given 1 mg/day or 5 mg/day vitamin K1 for one month
decreases, overall %Glu-OC fell from a median of 46.8 to 29.1% (pre/post, both doses pooled)
Not recorded as a finding: the result compares a group with itself, not with a control
Supplementation also significantly reduced the overall %Glu-OC from a median of 46.8 to 29.1% (p<0.0003).
PMID 18511355 · one of two readings recorded this
serum vitamin K1 below optimal at baseline
increases
Of the 50% of subjects who were below the optimal serum vitamin K1 at baseline, all rose into the normal range with supplementation
PMID 18511355 · one of two readings recorded this
undercarboxylated osteocalcin (%Glu-OC), overall
decreases, p = 0.0003
Supplementation also significantly reduced the overall %Glu-OC from a median of 46.8 to 29.1% (p<0.0003)
PMID 18511355 · one of two readings recorded this
participants with insufficient baseline phylloquinone
n = 222
222 participants had insufficient phylloquinone concentrations (≤1 nM) at baseline (114 in the treatment arm, 108 in the placebo arm), of whom 125 achieved a concentration of >1 nM by the end of the study
PMID 18625626 · one of two readings recorded this
per-joint prevalence of radiographic hand osteoarthritis, joint space narrowing grade 2 or more and osteophytes, OARSI atlas on hand radiographs, logistic regression with GEE
no effect, joint space narrowing OR 1.04, 95% CI 0.68 to 1.57, p = 0.9, p = 0.9
Not recorded as a finding: a node exists but the paper states a different instrument or population
There was no effect of randomisation to vitamin K supplementation on prevalence of radiographic hand osteoarthritis (OR 1.03, 95% CI 0.80 to 1.34, p = 0.8), joint space narrowing (OR 1.04, 95% CI 0.68 to 1.57, p = 0.9) or osteophytes (OR 0.95, 95% CI 0.64 to 1.40, p = 0.8).
PMID 18625626 · one of two readings recorded this
per-joint prevalence of radiographic hand osteoarthritis (Kellgren-Lawrence grade 2 or more), joint space narrowing (OARSI grade 2 or more) and osteophytes on hand radiographs at 3 years
no effect, hand OA OR 1.03 (95% CI 0.80 to 1.34); joint space narrowing OR 1.04 (0.68 to 1.57); osteophytes OR 0.95 (0.64 to 1.40)
Not recorded as a finding: this platform holds no node for the endpoint
There was no effect of randomisation to vitamin K supplementation on prevalence of radiographic hand osteoarthritis (OR 1.03, 95% CI 0.80 to 1.34, p = 0.8), joint space narrowing (OR 1.04, 95% CI 0.68 to 1.57, p = 0.9) or osteophytes (OR 0.95, 95% CI 0.64 to 1.40, p = 0.8).
PMID 18625626 · one of two readings recorded this
prevalence of joint space narrowing
no effect, p = 0.9
joint space narrowing (OR 1.04, 95% CI 0.68 to 1.57, p = 0.9)
PMID 18625626 · one of two readings recorded this
prevalence of joint space narrowing
decreases, p = 0.02
trends towards 47% lower prevalence of joint space narrowing (95% CI 0.32 to 0.89, p = 0.02)
PMID 18625626 · one of two readings recorded this
prevalence of osteophytes
no effect, p = 0.8
osteophytes (OR 0.95, 95% CI 0.64 to 1.40, p = 0.8)
PMID 18625626 · one of two readings recorded this
prevalence of osteophytes
no effect, p = 0.5
osteophytes (OR = 0.88, 95% CI 0.56 to 1.40, p = 0.5)
PMID 18625626 · one of two readings recorded this
prevalence of radiographic hand osteoarthritis
no effect, p = 0.8
radiographic hand osteoarthritis (OR 1.03, 95% CI 0.80 to 1.34, p = 0.8)
PMID 18625626 · one of two readings recorded this
prevalence of radiographic hand osteoarthritis
no effect, p = 0.1
radiographic osteoarthritis (OR = 0.78, 95% CI 0.56 to 1.07, p = 0.1)
PMID 18625626 · one of two readings recorded this
prevalence of radiographic osteoarthritis in at least 1 first carpometacarpal joint
Overall, 52.9% had >2 hand joints, 34.9% had >2 distal interphalangeal joints, and 37.3% had ≥1 first carpometacarpal joint involved with radiographic osteoarthritis, respectively
PMID 18625626 · one of two readings recorded this
prevalence of radiographic osteoarthritis in more than 2 distal interphalangeal joints
Overall, 52.9% had >2 hand joints, 34.9% had >2 distal interphalangeal joints, and 37.3% had ≥1 first carpometacarpal joint involved with radiographic osteoarthritis, respectively
PMID 18625626 · one of two readings recorded this
prevalence of radiographic osteoarthritis in more than 2 hand joints
Overall, 52.9% had >2 hand joints, 34.9% had >2 distal interphalangeal joints, and 37.3% had ≥1 first carpometacarpal joint involved with radiographic osteoarthritis, respectively
PMID 18625626 · one of two readings recorded this
3-y change in osteoprotegerin between treatment groups
no effect
However, the mean difference in change in osteoprotegerin between the treatment groups was not statistically significant
PMID 18689371 · one of two readings recorded this
adherence to supplement (percentage of tablets consumed over 3 y)
was 89.1% for the group supplemented with the multivitamin with phylloquinone and 88.5% for the group who received the multivitamin without phylloquinone
PMID 18689371 · one of two readings recorded this
age-related bone loss (BMD)
no effect
Because there was no effect of vitamin K supplementation on circulating cytokine concentrations or on age-related bone loss
PMID 18689371 · one of two readings recorded this
antiinflammatory medication use
decreases, p = 0.01
Overall, use of statin medication significantly increased to 36%, and antiinflammatory medication use (steroidal or non-steroidal) significantly decreased to 13.4% by year 3 (both P < 0.01)
PMID 18689371 · one of two readings recorded this
association between change in CRP and change in total body BMD
increases, p = 0.01
with the exception of a significant positive association between change in CRP and change in total body BMD (P = 0.01)
PMID 18689371 · one of two readings recorded this
association of osteoprotegerin with total osteocalcin
no effect, p = 0.05
Serum osteoprotegerin was not associated with total osteocalcin in any model (all P > 0.05)
PMID 18689371 · one of two readings recorded this
association of plasma phylloquinone with CRP
decreases, p = 0.04
plasma phylloquinone was significantly and inversely associated with CRP and IL-6 in age- and sex-adjusted analyses (P = 0.04 and 0.02, respectively, 2-sided)
PMID 18689371 · one of two readings recorded this
association of plasma phylloquinone with IL-6
decreases, p = 0.02
plasma phylloquinone was significantly and inversely associated with CRP and IL-6 in age- and sex-adjusted analyses (P = 0.04 and 0.02, respectively, 2-sided)
PMID 18689371 · one of two readings recorded this
association of plasma phylloquinone with osteoprotegerin
increases, p = 0.02
plasma phylloquinone was positively associated with circulating osteoprotegerin in all models (P = 0.02)
PMID 18689371 · one of two readings recorded this
association of total osteocalcin with CRP
decreases, p = 0.01
an increase of 10 ng/mL in circulating osteocalcin was associated with a 0.73-fold decrease in CRP and a 0.84-fold decrease in IL-6 in fully adjusted models (all P < 0.01)
PMID 18689371 · one of two readings recorded this
association of total osteocalcin with IL-6
decreases, p = 0.01
an increase of 10 ng/mL in circulating osteocalcin was associated with a 0.73-fold decrease in CRP and a 0.84-fold decrease in IL-6 in fully adjusted models (all P < 0.01)
PMID 18689371 · one of two readings recorded this
association of %ucOC with IL-6
decreases, p = 0.01
The %ucOC was inversely associated with IL-6 and osteoprotegerin in all models (P < 0.01)
PMID 18689371 · one of two readings recorded this
association of %ucOC with osteoprotegerin
decreases, p = 0.01
The %ucOC was inversely associated with IL-6 and osteoprotegerin in all models (P < 0.01)
PMID 18689371 · one of two readings recorded this
baseline dietary phylloquinone intake
Reported intakes of phylloquinone were higher than current recommendations at baseline in both groups (183 ± 108 μg/d in the vitamin K treatment group and 172 ± 111 μg/d in the non–vitamin K treatment group)
PMID 18689371 · one of two readings recorded this
circulating cytokine concentrations
no effect
Because there was no effect of vitamin K supplementation on circulating cytokine concentrations or on age-related bone loss
PMID 18689371 · one of two readings recorded this
CRP concentration, end of study versus baseline
no effect
The mean concentrations of CRP and IL-6 at the end of the 3-y study did not significantly differ from baseline concentrations in either group or when data from the 2 groups were combined
PMID 18689371 · one of two readings recorded this
IL-6 concentration, end of study versus baseline
no effect
The mean concentrations of CRP and IL-6 at the end of the 3-y study did not significantly differ from baseline concentrations in either group or when data from the 2 groups were combined
PMID 18689371 · one of two readings recorded this
lumbar spine BMD change, groups combined
increases, p = 0.05
Increases in BMD at the lumbar spine (x̄ ± SD: 0.02 ± 0.05 g/cm2) and decreases in total body BMD (–0.01 ± 0.03 g/cm2) were observed between baseline and year 3 in both groups (P < 0.05)
PMID 18689371 · one of two readings recorded this
osteoprotegerin concentration, end of study versus baseline
increases, p = 0.01
A statistically significant increase overall was observed in the mean concentration of osteoprotegerin in both groups (P < 0.01, repeated-measures ANOVA)
PMID 18689371 · one of two readings recorded this
plasma phylloquinone
increases, p = 0.01
Plasma phylloquinone increased [P < 0.01, repeated-measures analysis of variance (ANOVA)] and %ucOC decreased (P < 0.01, repeated measures ANOVA) after 3 y in the group that received phylloquinone supplementation
PMID 18689371 · one of two readings recorded this
serum percentage undercarboxylated osteocalcin (%ucOC)
decreases, p = 0.01
Plasma phylloquinone increased [P < 0.01, repeated-measures analysis of variance (ANOVA)] and %ucOC decreased (P < 0.01, repeated measures ANOVA) after 3 y in the group that received phylloquinone supplementation
PMID 18689371 · one of two readings recorded this
statin medication use
increases, p = 0.01
Overall, use of statin medication significantly increased to 36%, and antiinflammatory medication use (steroidal or non-steroidal) significantly decreased to 13.4% by year 3 (both P < 0.01)
PMID 18689371 · one of two readings recorded this
total body BMD change, groups combined
decreases, p = 0.05
Increases in BMD at the lumbar spine (x̄ ± SD: 0.02 ± 0.05 g/cm2) and decreases in total body BMD (–0.01 ± 0.03 g/cm2) were observed between baseline and year 3 in both groups (P < 0.05)
PMID 18689371 · one of two readings recorded this
HOMA-IR
decreases
HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group
PMID 18697901 · one of two readings recorded this
HOMA-IR
no effect
There was no significant difference among men in HOMA-IR and plasma insulin at the 6-month visit
PMID 18697901 · one of two readings recorded this
HOMA-IR
decreases, p = 0.03
differences among men in HOMA-IR were still statistically different (P = 0.03), whereas there was attenuation in differences in the plasma insulin (P = 0.07)
PMID 18697901 · one of two readings recorded this
36-month change in fasting plasma insulin
decreases, p = 0.03
insulin, −0.46 [−1.56 to 0.65] vs. 1.47 [0.22 to 2.71], P = 0.03
PMID 18697901 · one of two readings recorded this
36-month change in HOMA-IR
decreases, p = 0.01
HOMA-IR, −0.11 [95% CI −0.40 to 0.19] vs. 0.47 [0.15 to 0.80], P = 0.01
PMID 18697901 · one of two readings recorded this
36-month change in percent undercarboxylated osteocalcin, treated versus control
decreases, p = 0.001
36-month changes in plasma phylloquinone and percent undercarboxylated osteocalcin were significantly different from those of the control group for both men and women (P < 0.001)
PMID 18697901 · one of two readings recorded this
36-month change in percent undercarboxylated osteocalcin
0.4 ± 17.7% for men and 2.3% ± 21.2% for women in the control group
PMID 18697901 · one of two readings recorded this
36-month change in percent undercarboxylated osteocalcin
0.4 ± 17.7% for men and 2.3% ± 21.2% for women in the control group
PMID 18697901 · one of two readings recorded this
36-month change in percent undercarboxylated osteocalcin
decreases
were −19.0 ± 23.4% for men and −19.3 ± 20.5% for women in the treated group
PMID 18697901 · one of two readings recorded this
36-month change in percent undercarboxylated osteocalcin
decreases
were −19.0 ± 23.4% for men and −19.3 ± 20.5% for women in the treated group
PMID 18697901 · one of two readings recorded this
36-month change in plasma phylloquinone, treated versus control
increases, p = 0.001
36-month changes in plasma phylloquinone and percent undercarboxylated osteocalcin were significantly different from those of the control group for both men and women (P < 0.001)
PMID 18697901 · one of two readings recorded this
36-month change in plasma phylloquinone
whereas the changes in the men and women in the control group were −0.2 ± 1.9 and 0.1 ± 1.3 nmol/l, respectively
PMID 18697901 · one of two readings recorded this
36-month change in plasma phylloquinone
whereas the changes in the men and women in the control group were −0.2 ± 1.9 and 0.1 ± 1.3 nmol/l, respectively
PMID 18697901 · one of two readings recorded this
36-month change in plasma phylloquinone
increases
The mean ± SD 36-month changes in plasma phylloquinone concentrations for men and women receiving the vitamin K supplement were 1.4 ± 2.5 and 2.3 ± 2.8 nmol/l, respectively
PMID 18697901 · one of two readings recorded this
36-month change in plasma phylloquinone
increases
The mean ± SD 36-month changes in plasma phylloquinone concentrations for men and women receiving the vitamin K supplement were 1.4 ± 2.5 and 2.3 ± 2.8 nmol/l, respectively
PMID 18697901 · one of two readings recorded this
association of plasma phylloquinone with BMI (triglyceride-adjusted partial correlation)
decreases, p = 0.02
we found that plasma phylloquinone concentrations were inversely associated with BMI in women, but not in men, after adjustment for plasma triglycerides (Pearson's partial r = −0.15, P = 0.02)
PMID 18697901 · one of two readings recorded this
change in body fat
increases, p = 0.001
In men, mean body weight decreased by 0.5 kg (P = 0.02) and body fat increased by 0.5% (P = 0.001), respectively
PMID 18697901 · one of two readings recorded this
change in body weight
decreases, p = 0.02
In men, mean body weight decreased by 0.5 kg (P = 0.02) and body fat increased by 0.5% (P = 0.001), respectively
PMID 18697901 · one of two readings recorded this
change in fasting plasma glucose
no effect
There were no statistically significant differences in changes in HOMA-IR, fasting plasma insulin, and glucose between women in the vitamin K–treated groups and control group
PMID 18697901 · one of two readings recorded this
change in fasting plasma insulin
no effect
There were no statistically significant differences in changes in HOMA-IR, fasting plasma insulin, and glucose between women in the vitamin K–treated groups and control group
PMID 18697901 · one of two readings recorded this
change in HOMA-IR
no effect
There were no statistically significant differences in changes in HOMA-IR, fasting plasma insulin, and glucose between women in the vitamin K–treated groups and control group
PMID 18697901 · one of two readings recorded this
change in percent body fat
increases, p = 0.002
Among women in our study, there was a significant increase in mean percent body fat of 0.6% over the 36 months (P = 0.002)
PMID 18697901 · one of two readings recorded this
fasting plasma glucose
no effect
Fasting plasma glucose concentrations among men did not differ between two study groups at any time point
PMID 18697901 · one of two readings recorded this
fasting plasma insulin
decreases
HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group
PMID 18697901 · one of two readings recorded this
fasting plasma insulin
no effect
There was no significant difference among men in HOMA-IR and plasma insulin at the 6-month visit
PMID 18697901 · one of two readings recorded this
fasting plasma insulin
unclear, p = 0.07
differences among men in HOMA-IR were still statistically different (P = 0.03), whereas there was attenuation in differences in the plasma insulin (P = 0.07)
PMID 18697901 · one of two readings recorded this
HOMA-IR at 36 months (primary), fasting plasma insulin and glucose (secondary), analysed separately in men and women after a significant sex-by-treatment interaction
decreases, HOMA-IR and insulin lower among men on supplement versus control at 36 months
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group after adjustment for baseline HOMA-IR, BMI, and weight change (Table 2).
PMID 18697901 · one of two readings recorded this
HOMA-IR at 36 months (primary), fasting plasma insulin and glucose (secondary), phylloquinone 500 ug/day versus multivitamin without phylloquinone
decreases, HOMA-IR and plasma insulin lower at 36 months among men in the supplement group; no significant differences among women
Not recorded as a finding: every result is a subgroup, with no whole-population estimate
HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group after adjustment for baseline HOMA-IR, BMI, and weight change (Table 2).
PMID 18697901 · one of two readings recorded this
health-related quality of life
no effect
There was no difference in health-related quality of life between groups
PMID 18922041 · one of two readings recorded this
baseline Gail breast cancer risk score
no effect
we calculated the Gail breast cancer risk score from baseline data and found that there was no difference between the vitamin K and the placebo groups (1.70% versus 1.71% risk of having invasive breast cancer in the next 5 y)
PMID 18922041 · one of two readings recorded this
cancer incidence
decreases, p = 0.02
Cancer incidence was lower in the vitamin K group than in the placebo group (three versus 12, p = 0.02; HR = 0.25, 95% CI 0.07 to 0.89)
PMID 18922041 · one of two readings recorded this
clinical fractures (time to first)
no effect, p = 0.08
hazard ratio [HR] = 0.41, 95% CI 0.15 to 1.18, p = 0.08 at 2 y
PMID 18922041 · one of two readings recorded this
clinical fractures (time to first)
decreases, p = 0.04
HR = 0.45, 95% CI 0.20 to 0.98, p = 0.04 at 4 y
PMID 18922041 · one of two readings recorded this
femoral neck BMD difference between groups
unclear
With the exception of a 1.7% difference in BMD at the femoral neck between the two groups at 36 mo
PMID 18922041 · one of two readings recorded this
fragility fractures
no effect, p = 0.11
six fractures sustained by four women on vitamin K and 11 fractures sustained by ten women on placebo, p = 0.11
PMID 18922041 · one of two readings recorded this
height change
no effect
There was no difference in mean changes in height between groups
PMID 18922041 · one of two readings recorded this
lumbar spine BMD percentage change over 2 y by DXA, primary outcome
-1.28% vs -1.22%, p = 0.84, difference -0.06% (95% CI -0.67% to 0.54%), p = 0.84
Not recorded as a finding: Sentence reports both arms decreased with a p value and no direction word for the between-arm contrast (direction_stated_but_not_significant)
In the vitamin K and placebo groups, respectively, BMD decreased by −1.28% and −1.22% (p = 0.84) (difference of −0.06%; 95% confidence interval [CI], −0.67% to 0.54%) at the lumbar spine and −0.69% and −0.88% (p = 0.51) (difference of 0.19%; 95% CI −0.37% to 0.75%) at the total hip over 2 y.
PMID 18922041 · one of two readings recorded this
lumbar spine BMD percentage change
no effect, p = 0.84
BMD decreased by −1.28% and −1.22% (p = 0.84) (difference of −0.06%; 95% confidence interval [CI], −0.67% to 0.54%) at the lumbar spine
PMID 18922041 · one of two readings recorded this
new morphometric vertebral fractures on VFA
no effect, p = 0.56
A total of 47 women had new morphometric vertebral fractures on VFA (most were Grade 1 fractures): 25 in the vitamin K group and 22 in the placebo group (p = 0.56)
PMID 18922041 · one of two readings recorded this
percentage of undercarboxylated osteocalcin (%ucOC) change
decreases, p = 0.0001
Vitamin K1 supplementation decreased ucOC and percentage of ucOC (−52.8% versus −3.5%, p < 0.0001, and −21.4% versus −2.0%, p < 0.0001 at 2 y, respectively)
PMID 18922041 · one of two readings recorded this
serum CTX
no effect, p = 0.07
serum CTX levels were similar between groups (0.58 ng/ml versus 0.54 ng/ml, p = 0.07)
PMID 18922041 · one of two readings recorded this
serum total osteocalcin
decreases, p = 0.0001
serum total OC levels decreased (21 ng/ml versus 24 ng/ml, p < 0.0001) in women supplemented with vitamin K compared to placebo
PMID 18922041 · one of two readings recorded this
serum vitamin K1 concentration by HPLC with fluorometric detection, 2 y
increases, 22.6 nmol/l versus 2.0 nmol/l at 2 y
Not recorded as a finding: No node for circulating phylloquinone after supplementation
Daily 5 mg of vitamin K1 supplementation increased serum vitamin K1 levels (22.6 nmol/l versus 2.0 nmol/l, p < 0.0001 at 2 y), but did not increase circulating vitamin K2 (menaquinones 4 and 7) levels.
PMID 18922041 · one of two readings recorded this
serum vitamin K1
increases, p = 0.0001
Daily 5 mg of vitamin K1 supplementation increased serum vitamin K1 levels (22.6 nmol/l versus 2.0 nmol/l, p < 0.0001 at 2 y)
PMID 18922041 · one of two readings recorded this
serum vitamin K2 (menaquinones 4 and 7)
no effect
but did not increase circulating vitamin K2 (menaquinones 4 and 7) levels
PMID 18922041 · one of two readings recorded this
total hip BMD percentage change
no effect, p = 0.51
−0.69% and −0.88% (p = 0.51) (difference of 0.19%; 95% CI −0.37% to 0.75%) at the total hip over 2 y
PMID 18922041 · one of two readings recorded this
undercarboxylated osteocalcin (ucOC) change
decreases, p = 0.0001
Vitamin K1 supplementation decreased ucOC and percentage of ucOC (−52.8% versus −3.5%, p < 0.0001, and −21.4% versus −2.0%, p < 0.0001 at 2 y, respectively)
PMID 18922041 · one of two readings recorded this
greater trochanter BMD
unclear, p = 0.011
When BMD was measured across time, C had a significant increase (P = .011) in greater trochanter BMD compared to E
PMID 19083462 · one of two readings recorded this
serum osteocalcin
no effect
There was no significant difference between E and C in serum osteocalcin concentrations over time
PMID 19083462 · one of two readings recorded this
shaft BMD
no effect, p = 0.067
The E group had a nonsignificant increase (P = .067) in shaft BMD compared to the C group
PMID 19083462 · one of two readings recorded this
urinary N-telopeptide
increases, p = 0.008
Urinary N-telopeptide levels increased significantly over time in E compared to C (P = .008)
PMID 19083462 · one of two readings recorded this
coronary artery calcium (CAC) progression, change in Agatston score over 3 years, phylloquinone 500 ug/d in a multivitamin versus multivitamin alone
no effect, ITT mean Agatston changes 27 +/- 6 versus 37 +/- 7, no difference
Not recorded as a finding: this platform holds no node for the endpoint
In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively.
PMID 19386744 · one of two readings recorded this
coronary artery calcium progression, change in Agatston score over 3 years
no effect, mean changes in Agatston scores 27 and 37, phylloquinone versus control, intention-to-treat
Not recorded as a finding: this platform holds no node for the endpoint
In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively.
PMID 19386744 · one of two readings recorded this
coronary artery calcium progression (change in Agatston score)
no effect
In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively
PMID 19386744 · one of two readings recorded this
coronary artery calcium progression
decreases, p = 0.03, n = 367
In a subgroup analysis of participants who were > or =85% adherent to supplementation (n = 367), there was less CAC progression in the phylloquinone group than in the control group (P = 0.03)
PMID 19386744 · one of two readings recorded this
coronary artery calcium progression
decreases, p = 0.04
those who received phylloquinone supplements had 6% less progression than did those who received the multivitamin alone (P = 0.04)
PMID 19386744 · one of two readings recorded this
serum matrix Gla protein (MGP) change as explanation for CAC progression decrease
no effect
Phylloquinone-associated decreases in CAC progression were independent of changes in serum MGP
PMID 19386744 · one of two readings recorded this
HOMA-IR at 12 months
no effect
at 12 mo, HOMA-IR was 2.13 ± 0.38 and 1.47 ± 0.22 in the experimental and control groups, respectively
PMID 20881072 · one of two readings recorded this
HOMA-IR at 6 months
no effect
at 6 mo, HOMA-IR was 2.24 ± 0.54 and 1.52 ± 0.23 in the experimental and control groups, respectively
PMID 20881072 · one of two readings recorded this
HOMA-IR at baseline
no effect
Before administration of the placebo or phylloquinone, total osteocalcin, ucOC, glucose, and insulin concentrations and HOMA-IR (1.24 ± 0.15 for the control group compared with 1.93 ± 0.37 for the experimental group) did not differ
PMID 20881072 · one of two readings recorded this
Serum ucOC concentration at 12 months
decreases, p = 0.001
At 12 mo, serum ucOC concentrations were 0.92 ± 0.09 ng/mL and 3.13 ± 0.26 ng/mL (P < 0.001) in experimental and control groups, respectively
PMID 20881072 · one of two readings recorded this
Serum ucOC concentration at 6 months
decreases, p = 0.001
At 6 mo, serum ucOC concentrations in the experimental group were 0.96 ± 0.08 ng/mL compared with 2.94 ± 0.27 ng/mL in the control group (P < 0.001)
PMID 20881072 · one of two readings recorded this
Serum ucOC concentration, decrease in magnitude
decreases
Despite a decrease of ≈200% in ucOC concentrations, HOMA-IR was similar in the 2 groups at 6 and 12 mo
PMID 20881072 · one of two readings recorded this
serum undercarboxylated osteocalcin (ucOC), 6 and 12 months
Not recorded as a finding: Direction is carried only by the two concentrations in the sentence, with no direction word naming the compound's effect
At 6 mo, serum ucOC concentrations in the experimental group were 0.96 ± 0.08 ng/mL compared with 2.94 ± 0.27 ng/mL in the control group (P < 0.001).
PMID 20881072 · one of two readings recorded this
serum undercarboxylated osteocalcin (ucOC) concentration
Not recorded as a finding: direction carried only by the estimates, no direction word in the sentence
At 12 mo, serum ucOC concentrations were 0.92 ± 0.09 ng/mL and 3.13 ± 0.26 ng/mL (P < 0.001) in experimental and control groups, respectively.
PMID 20881072 · one of two readings recorded this
Total serum osteocalcin concentration at 6 and 12 months
no effect
After treatment, total osteocalcin concentrations were similar at 6 and 12 mo
PMID 20881072 · one of two readings recorded this
Chance of reaching at least 85% of time with INR within the therapeutic range
increases
The patients from both the 100 μg group and the 150 μg group had a 2-fold higher chance of reaching at least 85% of time with the International Normalized Ratio within the therapeutic range
PMID 21193422 · one of two readings recorded this